Unfreezing liquid for ova or embryos and preparation method and unfreezing method thereof

By using a thawing solution containing synthetic serum substitutes, fatty acid supplements, and ice crystal inhibitors, combined with a gradient thawing method, the problem of cell damage caused by vitrification was solved, improving the survival rate and developmental capacity of oocytes or embryos, and reducing the risk of thawing.

CN118979012AInactive Publication Date: 2024-11-19SHANGHAI BEILI YONGXING MEDICAL INSTR CO LTD
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202411304744.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In existing embryo freezing technologies, the vitrification process causes cell damage, resulting in reduced survival and developmental capacity after thawing. Furthermore, traditional thawing solutions may contain animal serum components with unknown risks.

Method used

A thawing solution containing synthetic serum substitutes, fatty acid supplements, ice crystal inhibitors, and thawing protectants was used to reduce water crystal formation and osmotic stress through a gradient thawing method, thereby improving cell survival and development.

Benefits of technology

It significantly improved the survival rate and developmental capacity of eggs or embryos after thawing, reduced the risk of pathogenic microbial contamination, and increased embryo implantation and pregnancy rates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979012A_ABST
    Figure CN118979012A_ABST
Patent Text Reader

Abstract

The invention discloses a thawing liquid for ova or embryos and a preparation method thereof, and is characterized in that the thawing liquid comprises a thawing liquid A, a thawing liquid B and a thawing liquid C. The thawing liquid A and the thawing liquid B comprise a basic culture medium, a synthetic serum substitute, an ice crystal inhibiting material, a fatty acid supplement and a thawing protective agent; the unfreezing solution C comprises a basic culture medium, a synthetic serum substitute, fatty acid and an unfreezing protective agent. The invention also discloses a thawing method for ova or embryos, which can effectively control the growth of ice crystals, promote the developmental ability and obviously improve the damage of the thawing process to cells or tissues; through distributed unfreezing, the cost is saved; when used for unfreezing ova and embryos, the unfreezing agent can reduce permeation damage and improve the survival rate of ova or embryos.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to embryo engineering, and in particular to a thawing solution and a thawing method for eggs or embryos. Background Art

[0002] Embryo freezing technology refers to cryopreservation, which means storing biological materials under liquid nitrogen. This technology slows down or stops cell metabolism and division, and can continue to develop once normal physiological temperature is restored. The most mainstream technology in the current embryo freezing technology is vitrification, which can reduce the damage to the internal structure during the freezing process. It uses cryoprotectants (such as DMSO) to solidify when frozen, changing from a liquid to a structureless vitrified state. This vitrified state can maintain the molecular and ion distribution of its solution state, and can inhibit the formation of ice crystals in cells by rapidly cooling. Eggs or embryos frozen by vitrification have a higher pregnancy success rate. However, the thawing and recovery process of vitrified eggs or embryos should be as fast and smooth as possible to reduce irreversible damage to the eggs or embryos during the thawing process.

[0003] Existing studies have found that during the vitrification process, cryoprotectants will destroy the cell membrane phospholipid bilayer, induce the transport of triglycerides in cell lipid droplets to the cytoplasm, and even activate lipid droplet autophagy; at the same time, fatty acids in eggs or embryos will also partially dissolve in cryoprotectants and flow out of the cytoplasm when the cells are thawed. Fatty acids are the source of energy during embryonic development and are present in large quantities in the fallopian tubes and uterus. After the fatty acids in the cells are transported to the mitochondria, they are metabolized to acetyl-CoA through β-oxidation catalyzed by enzymes such as ACAA2 and HADHA. Acetyl-CoA then produces ATP through the tricarboxylic acid cycle (TCA cycle). Therefore, vitrification will destroy the synthesis of ATP in cells to a certain extent, resulting in a decrease in cell survival rate after thawing and a decrease in embryonic development ability.

[0004] Existing thawing solutions usually contain culture medium, buffer and thawing protective agent, which provide necessary substances and suitable growth environment for cell thawing. Since serum contains a variety of bioactive substances that can provide nutrition and protective factors, and also has the function of osmotic pressure regulation and pH buffering, it is a commonly used component in culture medium. However, serum, especially animal serum, contains unknown substances that may pose risks to eggs or embryos, so thawing solutions using serum substitutes are emerging. In addition, the formation of water crystals and osmotic stress caused by concentration differences during the thawing process also lead to a decrease in cell activity after thawing.

[0005] In summary, a thawing solution and a thawing method that are more suitable for eggs or embryos are needed. Summary of the invention

[0006] The technical problem to be solved by the present invention is to provide a thawing solution for eggs or embryos and a preparation method and a thawing method thereof.

[0007] In order to solve the above technical problems, the technical solution of the present invention is:

[0008] In a first aspect, the present invention provides a thawing solution for eggs or embryos, including thawing solution A, thawing solution B and thawing solution C, wherein thawing solution A and thawing solution B include a basal culture medium, a synthetic serum substitute, an ice crystal inhibition material, a fatty acid supplement and a thawing protectant, and thawing solution C includes a basal culture medium, a synthetic serum substitute, a fatty acid supplement and a thawing protectant.

[0009] Preferably, the content of ice crystal inhibiting material in the thawing solution B is less than that in the thawing solution A, the content of synthetic serum substitute in the thawing solution B is greater than that in the thawing solution A, and the content of synthetic serum substitute in the thawing solution C is equal to that in the thawing solution B.

[0010] More preferably, the volume fraction of the synthetic serum substitute in the thawing solution A is 10% to 30%, and the content of the ice crystal inhibiting material is 0.06 to 0.1 g·L -1 The volume fraction of the synthetic serum substitute in the thawing solution B is 15% to 30%, and the content of the ice crystal inhibiting material in the thawing solution B is 0.04 to 0.06 g·L -1 ; The volume fraction of the synthetic serum substitute in the thawing solution C is 15% to 30%.

[0011] Preferably, the basal medium comprises antibiotics and a buffer.

[0012] Preferably, the fatty acid supplement includes any one or more of unsaturated fatty acids, saturated fatty acids, unsaturated fatty acid glycerides and saturated fatty acid glycerides; the volume fraction of the fatty acids in the thawing solution A, thawing solution B and thawing solution C is equal, which is 1.0% to 2.0%.

[0013] More preferably, the unsaturated fatty acids include any one or more of arachidonic acid, linoleic acid, linolenic acid, γ-linolenic acid, oleic acid, EPA, DHA, and conjugated linoleic acid, and the saturated fatty acids include any one or more of lauric acid, myristic acid, palmitic acid, and stearic acid.

[0014] Preferably, the buffer is any one of phosphate buffer or HEPES buffer.

[0015] Preferably, the synthetic serum substitute comprises: functional proteins, growth factors, vitamins, phospholipids, cholesterol, trace elements, essential amino acids and non-essential amino acids.

[0016] More preferably, the functional protein includes one or more of recombinant human albumin, insulin, and transferrin; the growth factor includes one or more of fibroblast growth factor (FGF), insulin-like growth factor (IGF), and epidermal growth factor (EGF); the vitamins include B vitamins, vitamin C, and vitamin E; and the trace elements include one or more of iron, selenium, zinc, and copper.

[0017] Preferably, the ice crystal inhibiting material is one or more of glycerol, dimethyl sulfoxide (DMSO), ethylene glycol, trehalose, polyvinyl alcohol (PVA), and polyvinyl pyrrolidone (PVP).

[0018] Preferably, the content of the thawing protective agent in the thawing solution A is greater than the content of the thawing protective agent in the thawing solution B, and the content of the thawing protective agent in the thawing solution B is greater than the content of the thawing protective agent in the thawing solution C.

[0019] More preferably, the content of the thawing protective agent is 2.0 to 6.0 g·L -1 .

[0020] More preferably, the thawing protective agent includes polypeptide, glutathione, and α-lipoic acid.

[0021] More preferably, the polypeptide includes ZP3 polypeptide or ZP4 polypeptide, and the polypeptide also includes any one of L-Thr-L-Arg (TR), L-Thr-L-Pro (TP), L-Arg-L-Thr (RT), L-Pro-L-Thr (PT), L-Thr-L-Arg-L-Thr (TRT), L-Thr-L-Pro-L-Thr (TPT), L-Ala-L-Ala-L-Thr (AAT) and L-Thr-L-Cys-L-Thr (TCT) and combinations thereof.

[0022] In a second aspect, the present invention provides a method for preparing a thawing solution for eggs or embryos, comprising the following steps:

[0023] (1) Weighing corresponding amounts of synthetic serum substitute, ice crystal inhibiting material and thawing protective agent as the basis for preparing thawing solution A, thawing solution B and thawing solution C, ensuring that the content of ice crystal inhibiting material and thawing protective agent in thawing solution B is less than that in thawing solution A, the content of synthetic serum substitute in thawing solution B is greater than that in thawing solution A, the content of thawing protective agent in thawing solution C is less than that in thawing solution B, and the content of synthetic serum substitute in thawing solution C is equal to that in the thawing solution B;

[0024] (2) slowly dripping a fatty acid supplement having a volume fraction of 1.0% to 2.0% into thawing solution A, thawing solution B, and thawing solution C, respectively, to ensure that the volume fraction of the fatty acid supplement added to each thawing solution is equal;

[0025] (3) Pour the remaining basal medium into thawing solution A, thawing solution B, and thawing solution C respectively, ensuring that the volumes of thawing solution A, thawing solution B, and thawing solution C are equal;

[0026] (4) Adjust the pH of thawing solution A, thawing solution B and thawing solution C to 7.0-7.4 respectively.

[0027] In a third aspect, the present invention provides a method for thawing an egg or an embryo, comprising the following steps:

[0028] (1) Pour 4 mL of thawed solution A into a 35 mm culture dish and warm it to 37°C as solution 1.

[0029] (2) Take 300 μL of thawing solution B as solution 2, and take 600 μL of thawing solution C and divide it into two equal parts, respectively as solution 3 and solution 4;

[0030] (3) taking out the frozen eggs or embryos and placing them in solution 1 at 37°C for 1 min;

[0031] (4) Take out the eggs or embryos from solution 1, transfer them to solution 2, and place them at room temperature for 3 minutes;

[0032] (5) Take out the eggs or embryos from solution 2, transfer them to solution 3, and place them at room temperature for 3 minutes;

[0033] (6) Taking out the egg or embryo from solution 3, transferring it to the surface of solution 4, observing the condition of the egg or embryo at room temperature, taking out the egg or embryo after it sinks to the bottom and transferring it to the surface of solution 4 again, taking out the egg or embryo after it sinks to the bottom again, and obtaining the thawed egg or embryo.

[0034] The above technical solution has the following beneficial effects:

[0035] (1) The present invention provides a thawing solution for eggs or embryos, including a synthetic serum substitute that can be used for thawing eggs or embryos, which does not contain animal serum, has lower toxicity, and reduces the risk of contamination by pathogenic microorganisms;

[0036] (2) The present invention provides a thawing solution for eggs or embryos, including an ice crystal inhibition material, which can effectively control the growth of water crystals during the thawing process, significantly improve the mechanical damage of water crystals to cells or tissues during the recovery process, and thus significantly improve the survival rate of eggs or embryos after thawing;

[0037] (3) The present invention provides a thawing solution for eggs or embryos, comprising one or more fatty acids or glycerides thereof, which can effectively improve the survival rate and developmental ability of eggs or embryos after thawing, so that more blastocysts can reach the A-grade standard, thereby significantly improving the embryo implantation rate, pregnancy rate and ongoing pregnancy rate;

[0038] (4) The present invention provides a method for thawing eggs or embryos. The thawing solution for eggs or embryos described in the present invention is used to gradually thaw eggs or cells, thereby reducing the formation of water crystals and the osmotic stress caused by concentration differences, and improving the survival rate and development ability of eggs or embryos. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 This is a microscopic image of a human oocyte at the GV stage thawed using the thawing solution for eggs or embryos described in Example 1;

[0040] Figure 2 This is a microscopic picture of a human oocyte at the MI stage thawed using the thawing solution for eggs or embryos described in Example 1.

[0041] Figure 3 These are fluorescence microscope images of oocytes in each group in Experimental Example 2 of the present invention.

[0042] Figure 4 This is a comparison chart of the relative fluorescence intensity of oocytes in each group in Experimental Example 2 of the present invention. DETAILED DESCRIPTION

[0043] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in each embodiment of the present invention described below can be combined with each other as long as they do not conflict with each other.

[0044] In the following embodiments, the components used in all thawing solutions are of the same type: the fatty acid supplements are DHA and lauric acid, and the volume fraction ratio is 1:1; the basal culture medium includes antibiotics and a buffer; the ice crystal inhibition material is a mixture of glycerol and polyvinyl alcohol, and the volume fraction ratio is 1:1; the thawing protectants include ZP3 polypeptide, glutathione, α-lipoic acid, L-Ala-L-Ala-L-Thr (AAT) and L-Thr-L-Cys-L-Thr (TCT).

[0045] Example 1

[0046] This embodiment provides a thawing solution for eggs or embryos, including thawing solution A, thawing solution B and thawing solution C. Thawing solution A and thawing solution B include a basal culture medium, a synthetic serum substitute, an ice crystal inhibiting material and a thawing protective agent; thawing solution C includes a basal culture medium, a synthetic serum substitute and a thawing protective agent. The components are described in Table 1.

[0047] Table 1

[0048]

[0049] Example 2

[0050] This embodiment provides a thawing solution for eggs or embryos, including thawing solution A, thawing solution B and thawing solution C. Thawing solution A and thawing solution B include a basal culture medium, a synthetic serum substitute, an ice crystal inhibiting material and a thawing protective agent; thawing solution C includes a basal culture medium, a synthetic serum substitute and a thawing protective agent. The components are described in Table 2.

[0051] Table 2

[0052]

[0053]

[0054] Example 3

[0055] This embodiment provides a thawing solution for eggs or embryos, including thawing solution A, thawing solution B and thawing solution C. Thawing solution A and thawing solution B include a basal culture medium, a synthetic serum substitute, an ice crystal inhibiting material and a thawing protective agent; thawing solution C includes a basal culture medium, a synthetic serum substitute and a thawing protective agent. The components are described in Table 3.

[0056] Table 3

[0057]

[0058] Example 4

[0059] This embodiment provides a method for preparing a thawing solution for eggs or embryos, comprising the following steps:

[0060] (1) Weighing corresponding amounts of synthetic serum substitute, ice crystal inhibiting material and thawing protective agent as the basis for preparing thawing solution A, thawing solution B and thawing solution C, ensuring that the content of ice crystal inhibiting material and thawing protective agent in thawing solution B is less than that in thawing solution A, the content of synthetic serum substitute in thawing solution B is greater than that in thawing solution A, the content of thawing protective agent in thawing solution C is less than that in thawing solution B, and the content of synthetic serum substitute in thawing solution C is equal to that in the thawing solution B;

[0061] (2) slowly dripping a fatty acid supplement having a volume fraction of 1.0% to 2.0% into thawing solution A, thawing solution B, and thawing solution C, respectively, to ensure that the volume fraction of the fatty acid supplement added to each thawing solution is equal;

[0062] (3) Pour the remaining basal medium into thawing solution A, thawing solution B, and thawing solution C respectively, ensuring that the volumes of thawing solution A, thawing solution B, and thawing solution C are equal;

[0063] (4) Adjust the pH of thawing solution A, thawing solution B and thawing solution C to 7.0-7.4 respectively.

[0064] Example 5

[0065] This embodiment provides a method for thawing eggs or embryos, comprising the following steps:

[0066] (1) Pour 4 mL of thawed solution A into a 35 mm culture dish and warm it to 37°C as solution 1.

[0067] (2) Take 300 μL of thawing solution B as solution 2, and take 600 μL of thawing solution C and divide it into two equal parts, respectively as solution 3 and solution 4;

[0068] (3) taking out the frozen eggs or embryos and placing them in solution 1 at 37°C for 1 min;

[0069] (4) Take out the eggs or embryos from solution 1, transfer them to solution 2, and place them at room temperature for 3 minutes;

[0070] (5) Take out the eggs or embryos from solution 2, transfer them to solution 3, and place them at room temperature for 3 minutes;

[0071] (6) Taking out the egg or embryo from solution 3, transferring it to the surface of solution 4, observing the condition of the egg or embryo at room temperature, taking out the egg or embryo after it sinks to the bottom and transferring it to the surface of solution 4 again, taking out the egg or embryo after it sinks to the bottom again, and obtaining the thawed egg or embryo.

[0072] Comparative Example 1

[0073] This embodiment provides a thawing solution for eggs or embryos, including thawing solution A, thawing solution B and thawing solution C. The difference from Example 1 is that the thawing solution A, thawing solution B and thawing solution C in Comparative Example 1 do not contain fatty acids.

[0074] Comparative Example 2

[0075] This embodiment provides a thawing solution for eggs or embryos, including thawing solution A, thawing solution B and thawing solution C. The difference from Example 1 is that the synthetic serum substitute in thawing solution A, thawing solution B and thawing solution C of Comparative Example 2 is replaced by bovine serum.

[0076] Comparative Example 3

[0077] This embodiment provides a thawing solution for eggs or embryos, including thawing solution A, thawing solution B and thawing solution C. The difference from Example 1 is that the thawing solution A and thawing solution B in Comparative Example 3 do not include ice crystal inhibiting materials.

[0078] Comparative Example 4

[0079] This embodiment provides a thawing solution for eggs or embryos, including thawing solution A, thawing solution B and thawing solution C, and the components are as described in Table 4.

[0080] Table 4

[0081]

[0082]

[0083] Experimental Example 1

[0084] In this experimental example, the thawing solution for eggs or embryos in Example 1 was used to thaw human oocytes, and the subsequent development of the eggs was observed. Figures 1-2 As shown, it can be observed that the thawed oocytes developed well.

[0085] Experimental Example 2

[0086] This experimental example studies the effects of the thawing solutions for eggs or embryos in Example 1 and Comparative Example 1 on the neutral lipid content in mouse MII stage oocytes. The frozen mouse MII stage oocytes were thawed using the thawing method for eggs or embryos described in Example 4 and the thawing solutions for eggs or embryos in Example 1 and Comparative Example 1.

[0087] Fresh mouse MII stage oocytes were used as the control group, and the intracellular neutral lipid content of oocytes in each group was detected by Nile red staining; at the same time, oocytes in each group were artificially inseminated by intracytoplasmic sperm injection (ICSI) technology, transferred to KSOM-AA medium for culture for at least 5 days (37℃, 5% CO2), and the development of fertilized oocytes in each group was continuously observed. Oocytes that produced the second polar body and formed male and female pronuclei were defined as normal fertilized oocytes.

[0088] The results of Nile red staining in the experimental example are as follows Figure 3 and Figure 4As shown. It can be seen that the fluorescence intensity of the oocytes in the comparative example 1 group is much lower than that of the fresh oocytes, while the fluorescence intensity of the embodiment 1 group does not decrease too obviously. It can be seen that compared with the fresh oocytes, the neutral lipid content of the oocytes in the comparative example 1 group is significantly reduced; although the neutral lipid content of the embodiment 1 group also decreases to a certain extent, it is significantly higher than that of the comparative example 1 group.

[0089] The ICSI fertilization and cultivation results in the experimental example are shown in Table 5.

[0090] Table 5 Statistics of ICSI fertilization results after thawing

[0091]

[0092]

[0093] There was little difference in the survival rate after thawing and the fertilization rate after ICSI fertilization in each group, but the embryo development rate of the example group was significantly higher than that of the control group after entering the morula stage. The thawing solution for eggs or embryos described in Example 1 had the most obvious effect on the survival rate and developmental ability of mouse oocytes after thawing.

[0094] From the experimental results of Examples 1 to 3 and Comparative Example 1, it can be seen that the developmental capacity of the mouse oocytes in the Examples is significantly higher because the thawing solution of the present invention contains fatty acids, which increases the intracellular lipid content, promotes intracellular β-oxidation to produce ATP, and thus improves the developmental capacity of the eggs after thawing.

[0095] From the experimental results of Examples 1 to 3 and Comparative Example 4, it can be seen that the developmental ability of the mouse oocytes in the examples is significantly higher because some components of the thawing solution A, thawing solution B and thawing solution C described in the present invention are gradient-differentiated, thereby reducing the osmotic stress on the mouse oocytes during the gradual thawing process.

[0096] From the experimental results of Examples 1 to 3 and Comparative Example 3, it can be seen that the thawing solution for eggs or embryos of the present invention can improve the developmental ability of mouse oocytes. This is because the present invention adds ice crystal inhibition material to reduce the irreversible damage to subsequent embryonic development caused by the formation of water crystals during the thawing process of mouse oocytes.

[0097] Experimental Example 3

[0098] This experimental example studies the effects of the thawing solutions for eggs or embryos of Examples 1 to 3 and Comparative Examples 1 to 3 on the survival rate of mouse embryos. Mouse embryos were vitrified at the 4-cell stage and divided into 6 groups according to Examples 1 to 3 and Comparative Examples 1 to 3. The frozen mouse embryos were thawed using the thawing method for eggs or embryos described in Example 4 and the thawing solutions for eggs or embryos of Examples 1 to 3 and Comparative Examples 1 to 3.

[0099] After thawing, the embryos were immediately placed in EmbryoSlide embryo culture plates and cultured individually in 180-μL culture medium containing paraffin oil. The culture medium was placed in the Embryoscope+ extended culture system and cultured for 3 days (37°C, 5% CO2).

[0100] EmbryoViewer software was used to evaluate embryonic development, and the time points of the following events were recorded and analyzed: the beginning of the 5-cell stage (t5), 6-cell stage (t6), 7-cell stage (t7), and 8-cell stage (t8), the beginning of embryo compaction (tSC), the completion of compaction (tM), and the beginning of blastocyst formation (tSB). Blastocyst quality was also evaluated, and blastocysts classified as AA, AB, BA, or BB were classified as having good morphology.

[0101] The experimental results are shown in Table 6.

[0102] Table 6 Statistics of mouse embryo quality after thawing

[0103]

[0104]

[0105] From the data in Table 5, it can be seen that the thawing solution for eggs or embryos described in the present invention has a survival rate of more than 93% in the mouse embryo survival rate experiment, the proportion of embryos that develop into morula stage is more than 90%, and the proportion of embryos that develop into blastocysts is more than 70%. Among them, the thawing solution for eggs or embryos described in Example 1 has the most obvious effect on the survival rate and development ability of mouse embryos.

[0106] From the experimental results of Examples 1 to 3 and Comparative Example 1, it can be seen that the embryonic development ability of the mice in the examples is significantly higher because the thawing solution of the present invention contains fatty acids, which increases the intracellular lipid content, promotes intracellular β-oxidation to produce ATP, and thus improves the thawing survival rate and development ability of the embryos.

[0107] From the experimental results of Examples 1 to 3 and Comparative Example 4, it can be seen that the mouse embryonic development ability of the examples is significantly higher because some components of the thawing solution A, thawing solution B and thawing solution C described in the present invention are gradient-differentiated, thereby reducing the osmotic stress on the mouse embryos during the gradual thawing process.

[0108] From the experimental results of Examples 1 to 3 and Comparative Example 3, it can be seen that the thawing solution for eggs or embryos of the present invention can improve the survival rate of mouse embryos. This is because the present invention adds ice crystal inhibition materials to reduce the irreversible damage to embryonic development caused by the formation of water crystals during the thawing process of mouse embryos.

[0109] The embodiments of the present invention are described in detail above, but the present invention is not limited to the described embodiments. For those skilled in the art, various changes, modifications, substitutions and variations of these embodiments are made without departing from the principles and spirit of the present invention, and still fall within the scope of protection of the present invention.

Claims

1. A thawing solution for eggs or embryos, characterized in that: It includes thawing liquid A, thawing liquid B and thawing liquid C; The thawing solution A and the thawing solution B include a basal culture medium, a synthetic serum substitute, an ice crystal inhibiting material, a fatty acid supplement and a thawing protective agent, and the thawing solution C includes a basal culture medium, a synthetic serum substitute, a fatty acid supplement and a thawing protective agent; The fatty acid supplement includes any one or more of unsaturated fatty acids, saturated fatty acids, unsaturated fatty acid glycerides and saturated fatty acid glycerides. The volume fraction of the fatty acid supplement in the thawing solution A, thawing solution B and thawing solution C is equal, which is 1.0% to 2.0%; the basic culture medium includes antibiotics and a buffer.

2. The thawing solution for eggs or embryos according to claim 1, characterized in that: The content of the ice crystal inhibiting material in the thawing solution B is less than that in the thawing solution A, the content of the synthetic serum substitute in the thawing solution B is greater than that in the thawing solution A, and the content of the synthetic serum substitute in the thawing solution C is equal to that in the thawing solution B; the volume fraction of the synthetic serum substitute in the thawing solution A is 10% to 30%, and the content of the ice crystal inhibiting material is 0.06 to 0.1 g·L -1 The volume fraction of the synthetic serum substitute in the thawing solution B is 15% to 30%, and the content of the ice crystal inhibiting material in the thawing solution B is 0.04 to 0.06 g·L -1 .

3. The thawing solution for eggs or embryos according to claim 1, characterized in that: The unsaturated fatty acids include any one or more of arachidonic acid, linoleic acid, linolenic acid, γ-linolenic acid, oleic acid, EPA, DHA, and conjugated linoleic acid; The saturated fatty acid includes any one or more of lauric acid, myristic acid, palmitic acid and stearic acid.

4. The thawing solution for eggs or embryos according to claim 1, characterized in that: The synthetic serum substitute comprises: functional proteins, growth factors, vitamins, phospholipids, cholesterol, trace elements, essential amino acids and non-essential amino acids.

5. The thawing solution for eggs or embryos according to claim 4, characterized in that: The functional protein includes one or more of recombinant human albumin, insulin, and transferrin; The growth factor includes one or more of fibroblast growth factor (FGF), insulin-like growth factor (IGF), and epidermal growth factor (EGF); The vitamins are vitamin B group, vitamin C and vitamin E; The trace elements include one or more of iron, selenium, zinc and copper.

6. The thawing solution for eggs or embryos according to claim 1, characterized in that: The ice crystal inhibiting material is one or more of glycerol, dimethyl sulfoxide (DMSO), ethylene glycol, trehalose, polyvinyl alcohol (PVA), and polyvinyl pyrrolidone (PVP); The buffer is any one of phosphate buffer or HEPES buffer.

7. The thawing solution for eggs or embryos according to claim 1, characterized in that: The content of the thawing protective agent is 2.0 to 6.0 g·L -1 ; The content of the thawing protective agent in the thawing liquid A is greater than the content of the thawing protective agent in the thawing liquid B, and the content of the thawing protective agent in the thawing liquid B is greater than the content of the thawing protective agent in the thawing liquid C.

8. The thawing solution for eggs or embryos according to claim 1, characterized in that: The thawing protective agent includes polypeptide, glutathione and α-lipoic acid.

9. The thawing solution for eggs or embryos according to claim 8, characterized in that: The polypeptide includes a ZP3 polypeptide or a ZP4 polypeptide, and the polypeptide also includes any one of L-Thr-L-Arg (TR), L-Thr-L-Pro (TP), L-Arg-L-Thr (RT), L-Pro-L-Thr (PT), L-Thr-L-Arg-L-Thr (TRT), L-Thr-L-Pro-L-Thr (TPT), L-Ala-L-Ala-L-Thr (AAT) and L-Thr-L-Cys-L-Thr (TCT) and combinations thereof.

10. A method for preparing a thawing solution for eggs or embryos according to any one of claims 1 to 9, characterized in that: The following steps are involved: (1) Weighing corresponding amounts of synthetic serum substitute, ice crystal inhibiting material and thawing protective agent as the basis for preparing thawing solution A, thawing solution B and thawing solution C, ensuring that the content of ice crystal inhibiting material and thawing protective agent in thawing solution B is less than that in thawing solution A, the content of synthetic serum substitute in thawing solution B is greater than that in thawing solution A, the content of thawing protective agent in thawing solution C is less than that in thawing solution B, and the content of synthetic serum substitute in thawing solution C is equal to that in the thawing solution B; (2) slowly dripping a fatty acid supplement having a volume fraction of 1.0% to 2.0% into thawing solution A, thawing solution B, and thawing solution C, respectively, to ensure that the volume fraction of the fatty acid supplement added to each thawing solution is equal; (3) Pour the remaining basal medium into thawing solution A, thawing solution B, and thawing solution C respectively, ensuring that the volumes of thawing solution A, thawing solution B, and thawing solution C are equal; (4) Adjust the pH of thawing solution A, thawing solution B and thawing solution C to 7.0-7.4 respectively.

11. A method for thawing eggs or embryos, characterized in that: Thawing using a thawing solution for eggs or embryos according to any one of claims 1 to 9 comprises the following steps: (1) Pour 4 mL of thawed solution A into a 35 mm culture dish and warm it to 37°C as solution 1. (2) Take 300 μL of thawing solution B as solution 2, and take 600 μL of thawing solution C and divide it into two equal parts, respectively as solution 3 and solution 4; (3) taking out the frozen eggs or embryos and placing them in solution 1 at 37°C for 1 min; (4) Take out the eggs or embryos from solution 1, transfer them to solution 2, and place them at room temperature for 3 minutes; (5) Take out the eggs or embryos from solution 2, transfer them to solution 3, and place them at room temperature for 3 minutes; (6) Taking out the egg or embryo from solution 3, transferring it to the surface of solution 4, observing the condition of the egg or embryo at room temperature, taking out the egg or embryo after it sinks to the bottom and transferring it to the surface of solution 4 again, taking out the egg or embryo after it sinks to the bottom again, and obtaining the thawed egg or embryo.

Citation Information

Patent Citations

  • Vitrification thawing liquid and thawing method for ova and cleavage stage embryos

    CN111226909A

  • Vitrification freezing liquid and freezing method for ova or cleavage stage embryos

    CN111226910A

  • Application of thawing solution in thawing of cryo-preserved oocytes or embryos

    CN111789102A

  • Vitrification freezing unfreezing liquid set

    CN115777696A

  • Oral vaccines for producing mucosal immunity

    SG169576A1